They found two single-nucleotide polymorphisms (SNPs) in noncoding, functional regions of genes that regulate cancer progression, invasion, and metastasis (CHI3L2 SNP rs684559 and CD44 SNP rs353630). Hence, identified polymorphisms easily available at the time of PDAC diagnosis could be a noninvasive biomarker signature of prospective survival post-pancreatic resection. Read more . . .
Via a multicenter study of two independent cohorts with pancreatic ductal adenocarcinoma (PDAC) who underwent resection of their tumors, researchers evaluated noninvasive genetic biomarkers that could guide therapy in cases that were amenable to pancreatic cancer resection.